Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world. This virus can cause acute respiratory distress syndrome (ARDS) with a high fatality rate. In this phase I clinical trial, healthy volunteers in two dose cohorts will be vaccinated on a booster dose with RH109 Vaccine or placebo vaccine. The aim of the study is to assess the safety valuate the safety, reactogenicity, and immunogenicity of RH109 Vaccine.